Jayant Vaidya

Publications (123) View all

• Dataset: Podcast SABCS12 GS4 02 TARGIT-A trial

  Jayant S Vaidya, Frederik Wenz, Max Bulsara, David Joseph, Jeffrey S Tobias, Mo Keshtgar, Henrik Flyger, Samuele Massarut, Michael Alvarado, Christobel Saunders, [......], Helle Holtveg, Steffi Pigorsch, Mary Falzon, Eleanor Harris, April Matthews, Chris Brew-Graves, Ingrid Potyka, Tammy Corica, Norman Williams, Michael Baum
• Dataset: Podcast SABCS12 GS4 02 TARGIT-A trial

  Jayant S Vaidya, Frederik Wenz, Max Bulsara, David Joseph, Jeffrey S Tobias, Mo Keshtgar, Henrik Flyger, Samuele Massarut, Michael Alvarado, Christobel Saunders, [......], Helle Holtveg, Steffi Pigorsch, Mary Falzon, Eleanor Harris, April Matthews, Chris Brew-Graves, Ingrid Potyka, Tammy Corica, Norman Williams, Michael Baum
• Article: Targeted intraoperative radiotherapy for early breast cancer: TARGIT-A trial- updated analysis of local recurrence and first analysis of survival.

  Jayant S Vaidya, Frederik Wenz, Max Bulsara, David Joseph, Jeffrey S Tobias, Mo Keshtgar, Henrik Flyger, Samuele Massarut, Michael Alvarado, Christobel Saunders, [......], Helle Holtveg, Steffi Pigorsch, Mary Falzon, Eleanor Harris, April Matthews, Chris Brew-Graves, Ingrid Potyka, Tammy Corica, Norman Williams, Michael Baum
  Cancer 12/2012; 72(24 Suppl):Abstract No S4-2. · 4.77 Impact Factor
• Dataset: Podcast SABCS12 GS4 02 TARGIT-A trial

  Jayant S Vaidya, Frederik Wenz, Max Bulsara, David Joseph, Jeffrey S Tobias, Mo Keshtgar, Henrik Flyger, Samuele Massarut, Michael Alvarado, Christobel Saunders, [......], Helle Holtveg, Steffi Pigorsch, Mary Falzon, Eleanor Harris, April Matthews, Chris Brew-Graves, Ingrid Potyka, Tammy Corica, Norman Williams, Michael Baum
• Article: NSAID analgesic ketorolac used perioperatively may suppress early breast cancer relapse: particular relevance to triple negative subgroup.

  Michael Retsky, Rick Rogers, Romano Demicheli, William Jm Hrushesky, Isaac Gukas, Jayant S Vaidya, Michael Baum, Patrice Forget, Marc Dekock, Katharina Pachmann
  [show abstract] [hide abstract]
  ABSTRACT: To explain a bimodal relapse hazard among early stage breast cancer patients treated by mastectomy we postulated that relapses within 4 years of surgery resulted from something that happened at about the time of surgery to provoke sudden exits from dormant phases to active growth. Relapses at 10 months appeared to be surgery-induced angiogenesis of dormant avascular micrometastases. Another relapse mode with peak about 30 months corresponded to sudden growth from a single cell. Late relapses were not synchronized to surgery. This hypothesis could explain a wide variety of breast cancer observations. We have been looking for new data that might provide more insight concerning the various relapse modes. Retrospective data reported in June 2010 study of 327 consecutive patients compared various perioperative analgesics and anesthetics in one Belgian hospital and one surgeon. Patients were treated with mastectomy and conventional adjuvant therapy. Follow-up was average 27.3 months with range 13-44 months. Updated hazard as of September 2011 for this series is now presented. NSAID ketorolac, a common analgesic used in surgery, is associated with far superior disease-free survival in the first few years after surgery. The expected prominent early relapse events are all but absent. In the 9-18 month period, there is fivefold reduction in relapses. If this observation holds up to further scrutiny, it could mean that the simple use of this safe and effective anti-inflammatory agent at surgery might eliminate most early relapses. Transient systemic inflammation accompanying surgery could be part of the metastatic tumor seeding process and could have been effectively blocked by perioperative anti-inflammatory agents. In addition, antiangiogenic properties of NSAIDs could also play a role. Triple negative breast cancer may be the ideal group with which to test perioperative ketorolac to prevent early relapses.
  Breast Cancer Research and Treatment 05/2012; 134(2):881-8. · 4.43 Impact Factor